This research identifies genetic and biochemical strategies to overcome frataxin deficiency, the primary cause of Friedreich’s ataxia. By performing a genetic screen on C. elegans, scientists discovered that specific mutations in the FDX2 and NFS1 genes can bypass the need for frataxin by weakening the interaction between these two proteins. The study reveals that excess FDX2 actually inhibits the production of iron–sulfur clusters when frataxin levels are low, effectively blocking essential cellular energy processes. Experimental results demonstrate that partially reducing FDX2 levels restores mitochondrial function and improves growth in worms, human cell cultures, and mouse models. These findings suggest that maintaining a proper balance between frataxin and FDX2 is critical for health. Ultimately, the work proposes that targeting the reduction of FDX2 could serve as a promising new therapeutic approach for treating Friedreich’s ataxia.

References:

• Meisel J D, Joshi P R, Spelbring A N, et al. Mutations in mitochondrial ferredoxin FDX2 suppress frataxin deficiency[J]. Nature, 2025: 1-8.